dc.creator | Conrad, Karsten | |
dc.creator | Roeber, Nadja | |
dc.creator | Andrade, Luis E. C. [UNIFESP] | |
dc.creator | Mahler, Michael | |
dc.date.accessioned | 2020-07-17T14:02:33Z | |
dc.date.accessioned | 2022-10-07T21:00:24Z | |
dc.date.available | 2020-07-17T14:02:33Z | |
dc.date.available | 2022-10-07T21:00:24Z | |
dc.date.created | 2020-07-17T14:02:33Z | |
dc.date.issued | 2017 | |
dc.identifier | Clinical Reviews In Allergy & Immunology. Totowa, v. 52, n. 2, p. 202-216, 2017. | |
dc.identifier | 1080-0549 | |
dc.identifier | https://repositorio.unifesp.br/handle/11600/54860 | |
dc.identifier | 10.1007/s12016-016-8564-5 | |
dc.identifier | WOS:000397573000005 | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/4025941 | |
dc.description.abstract | Despite all the progress in the establishment of specific autoantibody assays, screening for antinuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells for quality-oriented laboratory diagnosis of ANA associated rheumatic diseases (AARD) remains indispensable but is not without limitations. Recent data on the relevance of the dense fine speckled (DFS) pattern and anti-DFS70 antibodies disclosed novel possibilities to optimize the serological stepwise diagnostics of AARD. The DFS pattern on HEp-2 cells is well differentiated from the classic "homogeneous" ANA pattern associated with dsDNA antibodies. This is the most frequent pattern in high titer ANA-positive healthy persons. The most characteristic ANA specificity associated with DFS pattern is the anti-DFS70 antibody (synonym LEDGF antibody). The prevalence of anti-DFS70 antibodies in AARD patients is significantly lower compared with the prevalence in ANA-positive healthy persons. There is a negative association between anti-DFS70 antibodies and AARD, especially if no concomitant AARD-specific autoantibodies are found. Isolated anti-DFS70 antibodies are detectable in less than 1 % of AARD but are detectable in 2-22 % of healthy persons. In the presence of an isolated anti-DFS70 antibody, the posttest probability for AARD is reduced significantly. The significance of anti-DFS70 antibodies as a criterion that helps to exclude AARD is also confirmed by follow-up studies on anti-DFS70 antibodies of positive, healthy individuals, who did not develop any AARD during a 4 year observation period. Consequently, anti-DFS70 antibodies are valuable novel biomarkers for better interpretation of positive ANA in cases of negative AARD-associated autoantibodies and should be integrated in modified test algorithms to avoid unnecessary referrals and examinations of ANA-positive persons. | |
dc.language | eng | |
dc.publisher | Humana Press Inc | |
dc.relation | Clinical Reviews In Allergy & Immunology | |
dc.rights | Acesso restrito | |
dc.subject | Antinuclear antibodies | |
dc.subject | Anti-DFS70 antibodies | |
dc.subject | ANA-associated rheumatic diseases | |
dc.subject | Diagnostics | |
dc.title | The Clinical Relevance of Anti-DFS70 Autoantibodies | |
dc.type | Artigo | |